PROTEOTYPE: HELPING THE WORLD TO BEAT CANCER

In the world of medical science there are heroes, aand no they don’t wear capes.

I met up with the lovely Emma and Wes from Cambridge-based medical tech firm Proteotype Diagnostics to produce this neat short film pitching for UK and EU grant funding. As well as being charm personified, their vision and their raison d’etre were of the noblest heighty. Put simply, their mission is to make multi-cancer early detection available globally. Watch the film to see just how these amazing people are shaking up the world of Cancer testing.

 

New Blood Test Could Revolutionize Cancer Screening

Something like half of us will be diagnosed with some form of cancer during our lifetime, yet 70% of cancer deaths result from cancers that currently have no available screening tests. In response to this challenge, researchers are developing a groundbreaking blood test that could detect multiple types of cancer, including those without existing screening options.

Proteotype’s new test, Enlighten, is a first-in-class Multi-Cancer Early Detection (MCED) tool designed to identify cancer at its earliest stages. Unlike traditional tests, Enlighten™ uses a non-invasive approach to measure the body’s response to tumor development, providing an innovative and more affordable way to detect early-stage cancers.

"Our goal is to deliver a step change in the way cancer is detected, improving health outcomes and reducing inequalities in healthcare," say the development team.

The technology enables whole blood samples to be stored at room temperature in standard EDTA collection tubes for up to 48 hours before processing, a feature that could revolutionize population-level screening. By allowing sample collection in pharmacies and mobile units, the test reduces pressure on primary healthcare providers, increasing accessibility for large-scale testing.

Currently, Enlighten™ is being clinically validated for several cancer types, including breast, colorectal, prostate, pancreatic, lung, melanoma, oesophageal, ovarian, bladder, and renal cancers. In the near future, the developers plan to expand their validation efforts to include stomach, liver, and thyroid cancers.

This breakthrough in cancer detection technology could be a major step forward in reducing cancer mortality rates and making early diagnosis more accessible to all.

 As Emma said, “together, we can help to beat cancer.”

adam rowleyComment